Ponatinib has inhibitory activity against BCR::ABL1 kinase, including a variant with threonine-to-isoleucine at position 315 (T315I) (4) but is associated with a higher risk of major arterial events than other TKIs among patients with CML (6). Here, BCR is linked to chronic myelogenous leukemia, BCR-ABL1 positive.